Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTLT Catalent	$63.48	$62.87	$53.51 ▼ $63.50	$11.52B	1.15	1.91 million shs	N/A
JNJ Johnson & Johnson	$159.90 +2.9%	$159.63	$140.68 ▼ $169.99	$385.33B	0.47	7.73 million shs	13.24 million shs
LLY Eli Lilly and Company	$788.62 -3.6%	$849.30	$711.40 ▼ $972.53	$747.75B	0.34	3.30 million shs	2.67 million shs
MRK Merck & Co., Inc.	$86.32 -0.3%	$91.18	$81.04 ▼ $134.63	$218.05B	0.4	11.10 million shs	12.68 million shs
PFE Pfizer	$24.30 -1.6%	$25.93	$24.21 ▼ $31.54	$137.79B	0.61	39.15 million shs	53.41 million shs
ZTS Zoetis	$159.34 -2.5%	$166.04	$144.80 ▼ $200.33	$73.21B	0.92	2.59 million shs	3.28 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTLT Catalent	0.00%	0.00%	0.00%	0.00%	+11.96%
JNJ Johnson & Johnson	+2.89%	-2.03%	-3.37%	+10.89%	+3.65%
LLY Eli Lilly and Company	-3.78%	-4.08%	-13.43%	+0.85%	+1.59%
MRK Merck & Co., Inc.	-0.33%	-1.46%	-6.74%	-12.93%	-33.55%
PFE Pfizer	-1.76%	-3.02%	-5.52%	-8.63%	-10.78%
ZTS Zoetis	-2.60%	-3.50%	-6.15%	-2.43%	-2.21%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTLT Catalent	0.8813 of 5 stars	1.0	0.0	0.0	4.6	0.6	0.0	1.9
JNJ Johnson & Johnson	4.2172 of 5 stars	2.3	3.0	4.2	3.9	2.6	2.5	0.6
LLY Eli Lilly and Company	4.9174 of 5 stars	3.4	5.0	3.3	4.0	3.2	2.5	1.9
MRK Merck & Co., Inc.	5 of 5 stars	4.3	5.0	5.0	3.9	2.7	3.3	3.8
PFE Pfizer	4.9715 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
ZTS Zoetis	4.5386 of 5 stars	3.5	3.0	4.2	0.4	3.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTLT Catalent	2.00	Hold	$63.33	-0.23% Downside
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	7.15% Upside
LLY Eli Lilly and Company	2.84	Moderate Buy	$1,009.72	28.04% Upside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$117.12	35.68% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	31.40% Upside
ZTS Zoetis	3.08	Buy	$215.90	35.50% Upside

Current Analyst Ratings Breakdown

Latest ZTS, LLY, CTLT, JNJ, MRK, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	JNJ Johnson & Johnson	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00
4/2/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/27/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/6/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$1,146.00
3/5/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$159.00 ➝ $171.00
3/5/2025	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$970.00 ➝ $1,100.00
2/27/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$200.00 ➝ $205.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTLT Catalent	$4.38B	2.63	$2.64 per share	24.04	$19.91 per share	3.19
JNJ Johnson & Johnson	$88.82B	4.34	$13.14 per share	12.17	$29.69 per share	5.39
LLY Eli Lilly and Company	$45.04B	16.60	$12.86 per share	61.34	$15.05 per share	52.40
MRK Merck & Co., Inc.	$64.17B	3.40	$3.00 per share	28.82	$14.85 per share	5.81
PFE Pfizer	$63.63B	2.17	$3.81 per share	6.38	$15.81 per share	1.54
ZTS Zoetis	$9.26B	7.71	$7.16 per share	22.26	$10.65 per share	14.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTLT Catalent	-$1.04B	-$2.26	N/A	47.02	2.69	-9.28%	-0.66%	-0.24%	N/A
JNJ Johnson & Johnson	$14.07B	$6.65	24.04	14.44	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$11.71	67.35	25.34	1.40	23.51%	85.24%	16.19%	5/1/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.73	12.83	8.72	0.77	26.67%	45.35%	17.36%	4/24/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.23	8.02	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.47	29.13	23.61	2.78	26.86%	53.82%	18.86%	5/6/2025 (Estimated)

Latest ZTS, LLY, CTLT, JNJ, MRK, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	LLY Eli Lilly and Company	$4.64	N/A	N/A	N/A	$12.77 billion	N/A
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/24/2025	N/A	MRK Merck & Co., Inc.	$2.16	N/A	N/A	N/A	$15.59 billion	N/A
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
2/13/2025	Q4 2024	ZTS Zoetis	$1.37	$1.40	+$0.03	$1.29	$2.30 billion	$2.32 billion
2/6/2025	Q4 2024	LLY Eli Lilly and Company	$5.45	$5.32	-$0.13	$4.88	$13.42 billion	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/22/2025	Q4 2024	JNJ Johnson & Johnson	$1.99	$2.04	+$0.05	$1.41	$22.44 billion	$22.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTLT Catalent	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$4.96	3.10%	+5.43%	74.59%	63 Years
LLY Eli Lilly and Company	$6.00	0.76%	+15.21%	51.24%	11 Years
MRK Merck & Co., Inc.	$3.24	3.75%	+5.73%	48.14%	14 Years
PFE Pfizer	$1.72	7.08%	+2.50%	121.99%	16 Years
ZTS Zoetis	$2.00	1.26%	+18.66%	36.56%	14 Years

Latest ZTS, LLY, CTLT, JNJ, MRK, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2025	ZTS Zoetis	quarterly	$0.50	1.2%	4/21/2025	4/21/2025	6/3/2025
1/28/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.32%	3/17/2025	3/17/2025	4/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTLT Catalent	1.38	2.51	1.96
JNJ Johnson & Johnson	0.43	1.11	0.86
LLY Eli Lilly and Company	2.00	1.15	0.97
MRK Merck & Co., Inc.	0.79	1.36	1.15
PFE Pfizer	0.63	1.00	0.73
ZTS Zoetis	1.09	1.75	1.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTLT Catalent	N/A
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
PFE Pfizer	68.36%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
CTLT Catalent	0.31%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.13%
MRK Merck & Co., Inc.	0.09%
PFE Pfizer	0.06%
ZTS Zoetis	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTLT Catalent	16,900	181.51 million	180.95 million	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	39,000	948.17 million	948.08 million	Optionable
MRK Merck & Co., Inc.	69,000	2.53 billion	2.53 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
ZTS Zoetis	14,100	447.79 million	447.08 million	Optionable

ZTS, LLY, CTLT, JNJ, MRK, and PFE Headlines

Recent News About These Companies

Zoetis Inc. (NYSE:ZTS) Shares Sold by Groupama Asset Managment

April 4 at 5:21 AM | marketbeat.com

Headlands Technologies LLC Invests $723,000 in Zoetis Inc. (NYSE:ZTS)

April 4 at 5:20 AM | marketbeat.com

This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years

April 3 at 8:45 AM | fool.com

Geode Capital Management LLC Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

April 3 at 5:55 AM | marketbeat.com

National Bank of Canada FI Has $50.37 Million Stake in Zoetis Inc. (NYSE:ZTS)

April 3 at 5:36 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Schroder Investment Management Group

April 3 at 4:39 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Bought by Arrowstreet Capital Limited Partnership

April 3 at 4:39 AM | marketbeat.com

Trexquant Investment LP Purchases New Holdings in Zoetis Inc. (NYSE:ZTS)

April 2 at 6:46 AM | marketbeat.com

Boston Family Office LLC Sells 6,365 Shares of Zoetis Inc. (NYSE:ZTS)

April 2 at 6:28 AM | marketbeat.com

Which Is a Better Investment, Jazz Pharmaceuticals plc or Zoetis Inc. Stock?

April 1 at 9:43 PM | aaii.com

Which Is a Better Investment, Corcept Therapeutics Incorporated or Zoetis Inc. Stock?

April 1 at 9:43 PM | aaii.com

2 Recession-Proof Stocks to Buy as Goldman Sachs Sounds Alarm

April 1 at 9:43 PM | moneymorning.com

HighPoint Advisor Group LLC Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

April 1 at 7:19 AM | marketbeat.com

B. Metzler seel. Sohn & Co. AG Has $33.38 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

April 1 at 6:57 AM | marketbeat.com

Alliancebernstein L.P. Sells 3,579,168 Shares of Zoetis Inc. (NYSE:ZTS)

April 1 at 6:31 AM | marketbeat.com

Edmond DE Rothschild Holding S.A. Has $43.58 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

April 1 at 6:22 AM | marketbeat.com

Axiom Investors LLC DE Acquires 52,125 Shares of Zoetis Inc. (NYSE:ZTS)

April 1 at 6:11 AM | marketbeat.com

AIA Group Ltd Raises Stock Holdings in Zoetis Inc. (NYSE:ZTS)

April 1 at 6:01 AM | marketbeat.com

Wellington Management Group LLP Boosts Stake in Zoetis Inc. (NYSE:ZTS)

April 1 at 5:53 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by O Shaughnessy Asset Management LLC

April 1 at 5:43 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by California Public Employees Retirement System

April 1 at 5:24 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Intel Foundry’s Moment of Truth: Will 18A Deliver?
By Jeffrey Neal Johnson | March 6, 2025
View Intel Foundry’s Moment of Truth: Will 18A Deliver?
Missed the Hims & Hers Rally? Clover Health Could Be Next
By Gabriel Osorio-Mazilli | March 5, 2025
View Missed the Hims & Hers Rally? Clover Health Could Be Next
Southwest Airlines Could Triple From Here—Here's How
By Gabriel Osorio-Mazilli | March 18, 2025
View Southwest Airlines Could Triple From Here—Here's How
Price Targets Show These 3 Stocks Near the $1 Trillion Mark
By Leo Miller | March 27, 2025
View Price Targets Show These 3 Stocks Near the $1 Trillion Mark

ZTS, LLY, CTLT, JNJ, MRK, and PFE Company Descriptions

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Johnson & Johnson NYSE:JNJ

$159.90 +4.54 (+2.92%)

Closing price 04/3/2025 03:59 PM Eastern

Extended Trading

$159.12 -0.78 (-0.49%)

As of 06:16 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$788.62 -29.60 (-3.62%)

Closing price 04/3/2025 03:59 PM Eastern

Extended Trading

$782.89 -5.73 (-0.73%)

As of 06:15 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$86.32 -0.28 (-0.32%)

Closing price 04/3/2025 03:59 PM Eastern

Extended Trading

$85.70 -0.62 (-0.72%)

As of 06:15 AM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer NYSE:PFE

$24.30 -0.41 (-1.64%)

Closing price 04/3/2025 03:59 PM Eastern

Extended Trading

$24.20 -0.09 (-0.37%)

As of 06:16 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Zoetis NYSE:ZTS

$159.34 -4.16 (-2.54%)

Closing price 04/3/2025 03:59 PM Eastern

Extended Trading

$158.30 -1.04 (-0.65%)

As of 05:43 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZTS, LLY, CTLT, JNJ, MRK, and PFE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZTS, LLY, CTLT, JNJ, MRK, and PFE Earnings

Compare Dividends

Latest ZTS, LLY, CTLT, JNJ, MRK, and PFE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZTS, LLY, CTLT, JNJ, MRK, and PFE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZTS, LLY, CTLT, JNJ, MRK, and PFE Company Descriptions

Catalent NYSE:CTLT

Johnson & Johnson NYSE:JNJ

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Pfizer NYSE:PFE

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools